210.31
+2.84
+(1.37%)
At close: April 17 at 3:30:00 PM GMT+5:30
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
Operating Cash Flow
5,893,100
3,839,700
2,659,500
3,548,500
5,126,600
Investing Cash Flow
-3,513,600
-2,295,200
-4,940,800
-6,185,300
-3,800,200
Financing Cash Flow
-1,929,900
-221,500
2,496,700
1,303,700
-110,400
End Cash Position
1,409,300
2,640,900
1,317,900
1,102,400
2,435,400
Capital Expenditure
-3,044,900
-3,032,500
-6,196,800
-4,638,000
-3,660,300
Issuance of Debt
821,400
1,482,400
3,321,900
4,486,700
3,562,000
Repayment of Debt
-2,328,400
-978,000
-1,656,800
-1,666,700
-1,869,700
Repurchase of Capital Stock
--
--
--
--
-23,100
Free Cash Flow
2,848,200
807,200
-3,537,300
-1,089,500
1,466,300
3/31/2021 - 4/22/2004
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
MVR0.BE Medivir AB
0.1372
-2.42%
PANACEABIO.NS Panacea Biotec Limited
522.95
+5.00%
HQ1.MU Oruka Therapeutics Inc. R
7.50
+2.04%
05Y.MU Vivoryon Therapeutics NV
1.7140
0.00%
BT3.BE Lineage Cell Therapeutics Inc
0.3600
-1.10%
DBV.F DBV Technologies S.A.
1.2520
+1.79%
PROT Proteonomix, Inc.
0.0000
0.00%
HTD.MU Corcept Therapeutics Inc
57.90
-3.60%
ICY.HA Incyte Corp
51.16
-0.31%
MVR0.F Medivir AB (publ)
0.1458
-1.88%